Perimenopause & Menopause FAQ
Perimenopause and menopause affect every woman differently - but one thing is consistent: too many women spend years struggling with symptoms that are dismissed, misdiagnosed, or inadequately treated. At Kass Precision Medicine, we believe this is unacceptable. We have dedicated our practice to mastering the art and science of menopause medicine, offering evidence-based, individualized hormone therapy and comprehensive women’s health care to patients throughout the greater Seattle area. The questions below are the ones we hear most often - and they deserve real, thorough answers. Visit our Menopause Medicine page to learn more about our approach.
FREQUENTLY ASKED QUESTIONS
What is the difference between perimenopause and menopause, and how do I know which one I’m in?
Menopause is officially defined as the point at which menstruation has ceased for 12 consecutive months, marking the end of a woman’s reproductive years. The average age of official menopause is 51, but the transition leading up to it - perimenopause - can begin as early as the late 30s or early 40s and last anywhere from four to ten or more years.
Here’s the critical nuance most women don’t hear from their doctors: you do not need to have stopped having periods to be experiencing perimenopausal symptoms. Hormonal fluctuation during perimenopause is erratic and not linear - estrogen and progesterone don’t decline in a straight line but rise and fall unevenly, sometimes dramatically. This unpredictability is what drives symptoms, and it can occur while your cycle continues. It is an exceedingly common experience for women to be told that because they’re still menstruating regularly they can’t be in menopause or perimenopause. This is simply not true, and it delays appropriate care by years. Read more in our blog: What is Perimenopause, and Am I In It?
What are the symptoms of perimenopause and menopause?
The symptom spectrum is broader than most women, or their doctors, realize. Common symptoms include:
Hot flashes and night sweats
Sleep disruption and insomnia
Brain fog and difficulty with word recall
Mood changes, anxiety, and depression
Fatigue and low energy
Loss of libido and painful intercourse
Vaginal dryness
Irregular periods
Weight gain and changes in fat distribution
Joint pain and heart palpitations
Frequent UTIs
Changes in skin and hair quality
Several of these - brain fog, mood changes, fatigue, low libido - are frequently misattributed to stress, burnout, or depression, leading to prescriptions for antidepressants or birth control when the root cause is hormonal. Notably, progesterone begins declining before estrogen during perimenopause, which is why anxiety, insomnia, and mood instability are often among the earliest symptoms.
At Kass Precision Medicine, we begin with a comprehensive diagnostic evaluation to accurately identify what’s driving your symptoms before recommending treatment. For a deeper look at the full symptom picture, read our blog: Watch Out for the First Signs of Early Menopause Symptoms.
Why should I take perimenopause and menopause seriously beyond just managing symptoms?
Because the hormonal changes of menopause do not just affect quality of life - they affect longevity and long-term disease risk in ways that are still insufficiently communicated to women. Once ovarian hormone production declines, women face a meaningfully elevated risk of:
Cardiovascular disease
Cognitive decline and Alzheimer’s disease
Osteoporosis
Type 2 diabetes and insulin resistance
Urogenital deterioration (i.e., UTIs and urinary sepsis risk)
Changes in dental and visual health
Consider the lifespan context: in 1908, the average woman lived to 51 - roughly the age of menopause onset. Today, women routinely live into their 80s and beyond, meaning they spend a third of their lives in a post-menopausal state. The hormonal environment of that final third matters enormously for health outcomes and quality of life. Estrogen protects bone, heart, brain, blood vessels, and urogenital tissue - its loss is not a neutral event. Proactively addressing the hormonal transition is not necessarily vanity medicine. The medical community might argue it could be disease prevention. Learn more in our blog: Finding the Right Menopause Treatments for Your Symptoms.
What is bioidentical hormone therapy, and is it considered safer than “synthetic hormones”?
Among evidence-based practitioners, bioidentical hormones - specifically 17β-estradiol and micronized progesterone - are considered to carry a meaningfully lower risk profile than the synthetic formulations that have historically dominated HRT prescribing.
Bioidentical hormones are generally considered to have a significantly more favorable safety profile than non bio-identical or non-physiologic formulations, a distinction that is both clinically meaningful and increasingly well-supported by evidence.
Bioidentical hormones are molecularly identical to the hormones your body naturally produces - specifically 17β-estradiol, micronized progesterone, and bioidentical testosterone. Because they interact with your hormone receptors exactly as endogenous hormones do, their physiologic effects are more predictable and their safety profile is distinctly better than non-bioidentical alternatives.
At Kass Precision Medicine, we use bioidentical hormones as the foundation of our HRT protocols in almost all circumstances, 17β-estradiol instead of Premarin, and micronized progesterone instead of Provera. The distinction matters enormously: the cardiovascular risks, thrombotic risks, and breast cancer signals widely associated with HRT in public perception are largely tied to synthetic formulations that are rarely used in modern evidence-based menopause medicine.
In order to tailor our approach to each patient’s physiology, lifestyle, and treatment goals, we use a variety of delivery formats including:
Transdermal patches
Creams and gels
Oral preparations
Injections and occasionally pellets
Learn more on our Hormone Replacement Therapy page.
Is Hormone Replacement Therapy (HRT) safe? I’ve heard it causes cancer.
This is one of the most important questions in all of women’s medicine - and the fear surrounding HRT has caused enormous harm by keeping appropriate treatment away from millions of women for decades.
The concern originates from the 2002 Women’s Health Initiative (WHI) trial, which reported elevated risks of breast cancer, stroke, and blood clots and triggered widespread panic and mass discontinuation of HRT. What was never clearly communicated is that the WHI used non-bioidentical hormones - specifically Premarin (conjugated equine estrogens derived from pregnant mare urine) and Provera (a synthetic progestin) - in a population of women whose average age was 63, many of whom had pre-existing cardiovascular disease, and who were initiating therapy a decade or more after menopause. These conditions bear little resemblance to how evidence-based HRT is practiced today. Subsequent analyses have consistently shown that the elevated breast cancer risk in the WHI was tied specifically to Provera (non bio-identical progestin), not the synthetic estrogen used in the trial and not bioidentical hormones. Women in the estrogen-only (premarin) arm of the WHI trial actually had lower breast cancer incidence than the placebo group. And critically, to date there are no studies indicating that bioidentical estradiol and micronized progesterone increase breast cancer risk. In 2025, the FDA altered the long-standing black box warning on HRT, reflecting a clearer and more accurate understanding of the evidence. Read our full breakdown: Hormone Replacement Therapy - FDA Removes Black Box Warning.
Interested in learning more?
What is the “timing window” for HRT, and why does it matter?
Initiating hormone replacement therapy within ten years of menopause onset - or ideally during perimenopause - is associated with the greatest cardiovascular and neurological benefits. When started early, 17β-estradiol has been shown to:
Reduce arterial stiffness
Slow the progression of carotid artery plaque
Lower LDL cholesterol
Confer meaningful cardioprotective effects.
Studies suggest estrogen may reduce the incidence of Alzheimer’s disease and offer protection against cardiovascular mortality - benefits that appear most pronounced when initiated within this critical early window. Waiting too long, particularly beyond a decade of hormone deficiency, may reduce these protective benefits - as was observed with the older, higher-risk participants in the WHI trial. This is why early recognition and proactive intervention matter. Many women spend years managing symptoms with antidepressants or birth control before finding a provider who addresses the hormonal root cause. The longer that window is delayed, the more potential benefit is left on the table. Learn more about our approach on our Menopause Medicine page.
Does HRT increase the risk of breast cancer?
The evidence here is nuanced and frequently misunderstood. The elevated breast cancer signal in the WHI was tied to Provera - a synthetic progestin - not to estrogen, and not to bioidentical hormones. Women in the estrogen-only arm of the WHI had lower breast cancer incidence than the placebo group.
Micronized progesterone has not been associated with increased breast cancer risk in observational studies, and recent evidence increasingly suggests that synthetic progestins, rather than estrogens, are the primary hormonal driver of breast cancer risk in HRT studies. The bottom line: the breast cancer risk that has dominated public perception of HRT for over two decades is largely a risk associated with synthetic progestins - not with the bioidentical formulations. That said, HRT is not appropriate for every woman - particularly those with a history of hormone-receptor-positive cancer - and candidacy is always evaluated carefully and individually. Read the full clinical breakdown on our HRT page.
What are the delivery options for bioidentical HRT?
At KPM we offer the full spectrum of bioidentical HRT delivery methods. The right choice depends on your individual physiology, preferences, and treatment goals:
Transdermal patches deliver estradiol with the most favorable thrombotic profile of all estrogen formulations, providing steady physiologic hormone levels with twice-weekly dosing. They're a reliable, low-maintenance option, though some patients find skin irritation or adhesion issues with certain formulations.
Creams and gels allow flexible, easily adjusted daily dosing of estradiol and testosterone. This flexibility is a genuine advantage, but daily application requires consistent compliance, and absorption can vary depending on skin site, hydration, and individual physiology. Some patients also find the texture or residue bothersome.
Oral micronized progesterone is commonly used at bedtime, where it also supports sleep quality and mood. It's well-tolerated for most patients, though oral administration does involve first-pass liver metabolism, which is worth discussing with your provider if you have specific health considerations.
Subcutaneous pellets - tiny compressed cylinders of bioidentical hormone - are inserted under the skin in a brief in-office procedure, delivering estradiol and testosterone continuously over 3 to 6 months. For some patients, this hands-free approach may offer a convenience advantage and support adherence. However, pellets have meaningful limitations: dosing cannot be adjusted or reversed once inserted, and there are legitimate clinical concerns about supraphysiologic hormone levels, particularly with testosterone pellets. Whether pellets are appropriate for you is an important conversation to have with your provider.
Dr. Kass works with each patient to determine the optimal formulation and route based on their complete clinical picture. Learn more on our Hormone Replacement Therapy page.
Should women consider testosterone therapy during perimenopause or menopause?
Testosterone is not just a male hormone, it is produced by the ovaries and adrenal glands in women throughout their lives, and women actually have three to four times more testosterone than estradiol in circulation. Yet it remains one of the most under-discussed and underutilized tools in perimenopause and menopause care.
Testosterone levels peak in a woman's 20s and fall approximately 25% by age 40, with a further decline of roughly 50% approaching and following menopause. This decline affects far more than libido. Testosterone plays a meaningful role in:
Mood stability and emotional resilience
Energy and motivation
Cognitive clarity
Muscle mass and body composition
Bone density
Exercise tolerance and recovery
Sleep quality
Urogenital tissue health
Many women describe the effects of declining testosterone as "losing my spark" - a phrase that aligns precisely with the hormone's documented roles in dopamine and serotonin modulation.
Randomized controlled trials support testosterone as a first-line therapy for Hypoactive Sexual Desire Disorder (HSDD), with evidence spanning improvements in desire, arousal, orgasmic function, and overall sexual satisfaction. Beyond sexual health, published clinical research demonstrates broader benefits across multiple domains, showing benefits in mood, cognition, body composition, musculoskeletal comfort, and vitality. A prospective study by Glaser, York, and Dimitrakakis (Maturitas, 2011) measured outcomes in 300 pre- and postmenopausal women using the validated Menopause Rating Scale (MRS) and found statistically significant improvement across all 11 symptom categories, including:
Mood, anxiety, and emotional resilience
Sleep quality
Hot flashes and sweating
Cognitive function and memory
Physical energy and fatigue
Joint and muscle comfort
Bladder function
Sexual desire, activity, and satisfaction
Both pre- and postmenopausal women responded similarly, and higher doses correlated with greater symptom relief. A companion review by the same authors (Maturitas, 2013) examined and refuted common concerns about testosterone in women, including cardiovascular risk, liver effects, breast cancer risk, and masculinization, concluding that many of these concerns stem from extrapolation from synthetic androgens or anabolic steroids, rather than from bioidentical testosterone therapy itself.
At KPM, testosterone is evaluated as part of every comprehensive hormone workup and, when indicated, prescribed in physiologic doses using bioidentical formulations. It is used off-label, as it is not FDA-approved for women in the US, but it is extensively studied and, for many women, the missing piece of the puzzle. Read more on our HRT page.
Will testosterone therapy make me look or sound more masculine?
This is one of the most common concerns women raise, and one of the most important misconceptions to address. Masculinizing effects such as voice deepening, significant facial hair growth, or clitoral enlargement rarely occur and generally with supraphysiologic doses used in conjunction with estrogen suppression, as in female-to-male transgender hormone therapy. At the therapeutic doses prescribed for menopausal women at KPM, these effects are not the goal and are not the typical outcome.
Some women may notice mild increases in body hair or occasional acne, both of which are dose-dependent and manageable with adjustments. The goal of testosterone therapy for women in perimenopause and menopause is restoration - and resolution of symptoms like loss of libido, mood changes etc. Providers should monitor patients closely for side effects and adjust dosing accordingly to ensure both efficacy and tolerability. For a full myth-busting breakdown, read our blog: Testosterone for Women.
Why am I gaining weight during menopause even though my diet hasn’t changed?
Weight gain during menopause, especially around the abdomen, is not a willpower problem or a sign that your diet has stopped working. The problem isn't your diet, or not entirely. Menopausal weight gain is driven by a convergence of hormonal, metabolic, and neuroendocrine shifts that fundamentally change how your body stores and burns energy. Women can gain roughly one to three pounds per year beginning in perimenopause, with the most pronounced change often being not the number on the scale but the redistribution of fat to the abdomen and visceral organs - where it carries greater metabolic and cardiovascular risk. Understanding these mechanisms is the first step toward addressing them.
The key drivers include:
Declining estrogen disrupts metabolic function on multiple fronts. Estradiol plays a direct role in insulin sensitivity, fat oxidation, and energy regulation - as levels fall, the body becomes more prone to insulin resistance, which promotes fat storage rather than fat burning. Estrogen also modulates leptin, the satiety hormone that signals fullness to the brain; as signaling becomes impaired, hunger increases and satisfaction from meals decreases. Critically, fat storage shifts from the hips and thighs, the subcutaneous pattern typical of reproductive years, to the abdomen, where visceral fat carries higher metabolic and cardiovascular risk.
Declining testosterone accelerates the loss of lean muscle mass, which is metabolically active tissue. Less muscle means a lower resting metabolic rate, meaning the body burns fewer calories at rest, even with no change in diet or activity. This is one of the most underrecognized contributors to menopause-related weight gain, and one of the strongest arguments for addressing testosterone deficiency directly.
Progesterone loss contributes to cortisol dysregulation, as progesterone has a natural calming, cortisol-buffering effect. Without it, stress responses become amplified, and elevated cortisol drives appetite, particularly cravings for calorie-dense foods, while directly promoting abdominal fat deposition.
Sleep disruption from night sweats, insomnia, and progesterone loss creates a compounding hormonal problem. Poor sleep elevates cortisol, suppresses leptin, and raises ghrelin - the hunger-stimulating hormone - creating a biochemical environment that increases appetite, reduces fullness signals, and makes weight management significantly harder regardless of diet or exercise habits.
Thyroid function becomes increasingly relevant during this transition. Estrogen influences thyroid hormone binding and metabolism, and many women develop subclinical hypothyroidism during perimenopause - often going undetected because standard TSH testing misses early dysfunction. Even mild thyroid insufficiency meaningfully slows metabolism and contributes to fatigue, fluid retention, and weight gain that can be mistakenly attributed to menopause alone.
The result is a genuine physiologic perfect storm - not a failure of willpower.
The most effective approach is multimodal: evidence-based nutrition, strength and interval training to preserve muscle mass, and addressing the hormonal root cause directly. HRT has been shown to meaningfully reduce menopausal fat accumulation and preserve lean muscle - women on hormone therapy consistently demonstrate better body composition outcomes than those without.
When additional support is needed, KPM’s Medical Weight Loss program offers a meaningful advantage over generic weight loss clinics: because we specialize in hormonal and metabolic medicine, we address the underlying dysfunctions driving weight gain - not just the weight itself. This includes evidence-based use of GLP-1 medications like Ozempic and Mounjaro, integrated within a comprehensive hormonal and metabolic treatment plan. Read more in our blog: Weight Gain During Menopause - What Can Be Done?
How does Kass Precision Medicine diagnose perimenopause and menopause?
No single lab test definitively confirms perimenopause - it is primarily a clinical diagnosis guided by symptom presentation, menstrual history, age, and laboratory findings interpreted in context. This is why many women are dismissed by providers who rely solely on hormone levels: a single blood draw during perimenopause can be misleading, as estrogen fluctuates dramatically from month to month. Normal or “in-range” values on one test do not exclude perimenopause.
At KPM, we run a comprehensive diagnostic panel that goes well beyond standard protocol, including:
Reproductive hormones: FSH, LH, estradiol, progesterone, inhibin B
Thyroid function
Metabolic markers
Cardiovascular biomarkers and inflammatory markers
Vitamin D and DHEA
Preventive imaging: DEXA scans for bone density, cardiac calcium scores, carotid intima-media thickness, and body composition analysis
The goal is not only to confirm a hormonal diagnosis but to build a complete picture of your current health trajectory and identify any risks that merit proactive intervention. Visit our Personalized Diagnostics page to learn more.
My doctor told me I’m too young to be in perimenopause. Could they be wrong?
Almost certainly, yes - if your symptoms suggest otherwise. One of the most damaging and persistent myths in women’s medicine is that perimenopause doesn’t begin until the late 40s or that it requires irregular periods to diagnose. In reality, hormonal fluctuation can begin in the early to mid-40s, and sometimes in the late 30s.
Even in women with regular cycles and seemingly normal hormone levels on a single blood draw, a number of symptoms can be early perimenopausal presentations. These include:
Worsening PMS
Sleep disruption
Mood changes
Brain fog
Declining libido
According to a 2021 survey, 73% of women aged 40 to 65 were not currently treating their menopause symptoms - a statistic that reflects how widespread this dismissal is. Dr. Kass and her team specialize in recognizing the full spectrum of perimenopausal presentations, including the subtle and frequently missed early signs. If you’ve been told your symptoms are “just stress” or that you’re too young to be dealing with hormonal changes, a consultation with a menopause specialist may be one of the most valuable conversations you have. Read more: What is Perimenopause, and Am I In It?
What should I expect at my first appointment at Kass Precision Medicine for menopause care?
Your first visit is a thorough, unhurried consultation - a genuine deep dive into your symptom history, menstrual history, medical background, medications, lifestyle, and health goals. A comprehensive lab panel is ordered, and Dr. Kass will discuss her findings with you in the context of your full clinical picture. Treatment recommendations are personalized - there is no one-size-fits-all protocol at KPM. Some women begin HRT relatively quickly; others benefit from additional diagnostic workup or a staged approach. The priority is accuracy, safety, and a treatment plan you feel fully informed about and confident in. Schedule a consultation to get started.
How do I get started with menopause care at Kass Precision Medicine in Bellevue, WA?
Contact Kass Precision Medicine here. Dr. Kass’s clinic is located in Bellevue, Washington, and serves women throughout the greater Seattle area, including Kirkland, Redmond, Issaquah, Mercer Island, Renton, and Bothell. If you’ve been struggling with symptoms that aren’t being taken seriously, or simply want a provider who is genuinely expert in menopause medicine, we’d love to be that resource for you.